KR860007377A - 충치예방제의 제조방법 - Google Patents

충치예방제의 제조방법 Download PDF

Info

Publication number
KR860007377A
KR860007377A KR1019860002072A KR860002072A KR860007377A KR 860007377 A KR860007377 A KR 860007377A KR 1019860002072 A KR1019860002072 A KR 1019860002072A KR 860002072 A KR860002072 A KR 860002072A KR 860007377 A KR860007377 A KR 860007377A
Authority
KR
South Korea
Prior art keywords
glucan
glucanohydrolase
extracted
dna
gene
Prior art date
Application number
KR1019860002072A
Other languages
English (en)
Other versions
KR940003689B1 (ko
Inventor
아이조 마쓰시로
Original Assignee
아이조 마쓰시로
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이조 마쓰시로 filed Critical 아이조 마쓰시로
Publication of KR860007377A publication Critical patent/KR860007377A/ko
Application granted granted Critical
Publication of KR940003689B1 publication Critical patent/KR940003689B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/743—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Agrobacterium; Rhizobium; Bradyrhizobium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01011—Dextranase (3.2.1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01084—Glucan 1,3-alpha-glucosidase (3.2.1.84), i.e. mutanase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Birds (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

내용 없음

Description

충치예방제의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 불용성글루칸의 구조식.
제2도는 스트랩토코쿠스 산기스의 세포질내에 존재하는 pGB 301 플라스미드의 유전자지도.
제3도는 pYEJ 001에 클로닝시킨-1.3글루카나제 유전자의 전사방향(합성 프로모터에서 개시되는 Cmr유전자와는 역방향)을 도시.
제6a도는 pMN 2의 제도를 도시.
제6b도는 pMN 3의 제조를 도시.

Claims (5)

  1. 충치균에 의해 생성되는 불용성글루칸의 분해효소인-1.3 글루칸 3-글루카노 하이드롤라제,-1.6 글루칸 6-글루카노 하이드롤라제, 또는 이들 효소 둘다를 생성하는 세균을 배양하고 ;
    상기 세균으로부터-1.3글루칸 3-글루카노하이드롤라제,-1.6글루칸 6-글루카노하이드롤라제, 또는 이들 둘다의 유전자 DNA를 추출하여 대장균의 플라스미드 DNA와 재조합시키고 ;
    상기 재조합플라스미드 DNA를 대장균에 도입시켜 형질발현시킨후 상기한-1.3글루칸 3-글루카노하이드롤라제,-1.6글루칸 6-글루카노하이드롤라제, 또는 이들 둘다의 유전자 DNA의 존재를 확인하고 ; 그후 상기 재조합플라스미드 DNA중의-1.3글루칸 3-글루카노하이드롤라제,-1.6글루칸 6-글루카노하이드롤라제, 또는 이들 둘다의 유전자 DNA를, 구강내 상재세균으로부터 추출한 플라스미드 DNA에 재조합시킴으로써 구강내 상재세균에 도입시켜 형질발현시킴을 특징으로 하여 충치예방제를 제조하는 방법.
  2. 제1항에 있어서,-1.3글루칸 3-글루카노하이드롤라제,-1.6글루칸 6-글루카노하이드롤라제, 또는 이들 둘다의 유전자 DNA를 바실루스 서쿨란스(Bacillus circulans) BC-8균으로부터 추출하는 방법.
  3. 제1항에 있어서,-1.3글루칸 3-글루카노하이드롤라제 유전자 DAA를 슈도모나스(Pseudomonas) SK-01균으로부터 추출하는 방법.
  4. 제1항에 있어서,-1.6글루칸 6-글루카노하이드롤라제 유전자 DNA를 코리네박테리움(Corynebac-terium)종 CB-8균으로부터 추출하는 방법.
  5. 제1항에 있어서,-1.6글루칸 6-글루카노하이드롤라제 유전자 DNA를 코리네박테리움 AK-01균으로부터 추출하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860002072A 1985-03-20 1986-03-20 충치예방제의 제조방법 KR940003689B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP5744385 1985-03-20
JP57443 1985-03-20
JP60-57443 1985-03-20

Publications (2)

Publication Number Publication Date
KR860007377A true KR860007377A (ko) 1986-10-10
KR940003689B1 KR940003689B1 (ko) 1994-04-27

Family

ID=13055798

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860002072A KR940003689B1 (ko) 1985-03-20 1986-03-20 충치예방제의 제조방법

Country Status (7)

Country Link
EP (1) EP0195672B1 (ko)
JP (1) JPS6225A (ko)
KR (1) KR940003689B1 (ko)
AU (1) AU592328B2 (ko)
CA (1) CA1321962C (ko)
DE (1) DE3681946D1 (ko)
SU (1) SU1720493A3 (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63185381A (ja) * 1987-01-27 1988-07-30 Aizo Matsushiro デキストラナ−ゼの製造方法
EP0311469A3 (en) * 1987-09-02 1990-05-30 Plant Genetic Systems N.V. Transformed lactic acid bacteria
US4810733A (en) * 1987-10-19 1989-03-07 Toyo Ink Mfg Co., Ltd Color concentrates
JPH02157228A (ja) * 1988-12-12 1990-06-18 Hitachi Ltd 微生物及びその利用方法
JPH0687776B2 (ja) * 1990-02-20 1994-11-09 愛三 松代 新規形質転換株およびその製造方法
JPH054927A (ja) * 1991-06-28 1993-01-14 Aizo Matsushiro 乳酸菌含有組成物及びその製造方法
IT1270123B (it) * 1994-10-05 1997-04-28 Dompe Spa Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
EP0882131A1 (en) * 1996-02-09 1998-12-09 Novo Nordisk Biotech, Inc. Polypeptides having mutanase activity and nucleic acids encoding same
ES2174248T3 (es) * 1996-04-16 2002-11-01 Novozymes As Composiciones para la eliminacion de una placa dental.
GB2327345B (en) * 1997-07-18 1999-06-23 Finnfeeds Int Ltd Use of an enzyme for manufacturing an agent for controlling bacterial infection
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
IL134936A0 (en) 1997-09-10 2001-05-20 Vion Pharmaceuticals Inc Genetically modified tumor-targeted bacteria with reduced virulence
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
EP1978979B1 (en) * 2006-01-04 2014-08-13 Wikström, Maude Probiotic oral health promoting product
MX343566B (es) 2010-08-31 2016-11-09 Centro Superior De Investig En Salud Publica (Csisp) * Composiciones y probioticos/prebioticos anticaries.
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
AU2022224569A1 (en) * 2021-02-17 2023-09-07 Colgate-Palmolive Company Prebiotic oral care compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57165312A (en) * 1981-04-03 1982-10-12 Handai Biseibutsubiyou Kenkyukai Production of oral composition
FR2529569B1 (fr) * 1982-07-02 1985-07-05 Pasteur Institut Microorganismes, notamment e. coli, transformes par une sequence d'adn originaire de c. thermocellum, compositions a activite cellulolytique issues de ces micro-organismes et procede pour les obtenir

Also Published As

Publication number Publication date
JPS6225A (ja) 1987-01-06
EP0195672A3 (en) 1988-07-06
DE3681946D1 (de) 1991-11-21
AU592328B2 (en) 1990-01-11
AU5493786A (en) 1986-09-25
EP0195672A2 (en) 1986-09-24
EP0195672B1 (en) 1991-10-16
SU1720493A3 (ru) 1992-03-15
KR940003689B1 (ko) 1994-04-27
CA1321962C (en) 1993-09-07

Similar Documents

Publication Publication Date Title
KR860007377A (ko) 충치예방제의 제조방법
Pollock The differential effect of actinomycin D on the biosynthesis of enzymes in Bacillus subtilis and Bacillus cereus
Grabski et al. Production, purification, and characterization of β-(1-4)-endoxylanase of Streptomyces roseiscleroticus
DK284985A (da) Biologisk ren aspergillus-kultur og et derfra udvundet lipolytisk enzym
KR850001528A (ko) 열안정성 글루코아밀라제의 제법
WO1989001970A3 (en) Transformed lactic acid bacteria
KR850001279A (ko) α-아밀라제의 제법
KR850005494A (ko) L-세린 디아미나아제 활동도가 결여된 돌연변이체 속
NZ214535A (en) Nuclease treatment of broth culture
KR830006307A (ko) 디아세틸 세팔로스포린의 새로운 제조방법
ES8504245A1 (es) Procedimiento para la obtencion de sarcosin-oxidasa
ATE147101T1 (de) Hypoglycosylierte recombinante glucoseoxidase
Holmes et al. Halophilic enzymes in cell-free extracts of Halobacterium salinarium
KR910001046A (ko) 비융합 단백질을 제조하기 위한 미생물내 발현용 발현벡터
KR870008029A (ko) 키산탄 검 합성을 위한 재조합 dna 플라스미드
DE69301238T3 (de) Eine methode zur induktion der malolaktischen gärung von wein oder fruchtsaft durch direktes animpfen mit einer nicht-aktivierten starterkultur
KR850005496A (ko) Dna 및 그의 이용
US5017479A (en) Process for multiplication of polysaccharide-producing microorganisms and use thereof in a polysaccharide production process
EA200200056A1 (ru) Ген streptomyces avermitilis, направляющий соотношение авермектинов b2:b1
Dekker et al. The β-mannanases elaborated by the phytopathogen Xanthomonas campestris
Shukla et al. Study of some parameters for the production of dextranase by Penicillium aculeatum
ES8802536A1 (es) Un procedimiento para producir adn recombinante que contiene un gen que codifica amilasa (como divisional de la solicitud de patente de invencion numero 543.860 presentada el 4 de junio de 1985)
Kim Production and Characterization of Extracellular $\beta $-Lactamase from Streptomyces aureofaciens SMF14
JPH07274960A (ja) β−マンナナーゼ生産菌及びβ−マンナナーゼの製法
KR960031612A (ko) BAlI 제한-변형 시스템의 효소를 코드화하는 유전자

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee